XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended 184 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Revenue         
Operating expenses:      
Research and development 1,494 708 67,093
Impairment of capital assets     386
Gain on deferred lease inducements     (497)
Acquired in-process research and development     13,094
General and administration 1,944 3,896 30,549
Loss from operations (3,438) (4,604) (110,625)
Other income (expense):      
Gain/(Loss) on derivative warrants 8,071 (3,251) 4,820
Settlement of Cadherin Biomedical Inc. litigation     (1,283)
Interest expense     (19)
Other income 9   264
Interest income 43 32 2,872
Total other income/(expense) 8,123 (3,219) 6,654
Net income/(loss) and total comprehensive loss $ 4,685 $ (7,823) $ (103,971)
Earnings/(loss) per share of common stock, basic $ 0.20 $ (0.49)  
Earnings/(loss) per share of common stock, diluted $ 0.19 $ (0.49)  
Weighted-average number of shares of common stock outstanding, basic 23,983 16,015  
Weighted-average number of shares of common stock outstanding, diluted 24,050 16,015